Viatris Expects its First Interchangeable Designation for Insulin Products

 Viatris Expects its First Interchangeable Designation for Insulin Products

Shots:

  • Viatris reported that its insulin glargine and insulin aspart products are both on track to be approved by the FDA as interchangeable by July 2021
  • The biosimilars are the proposed biosimilars of Sanofi’s Lantus and Novo Nordisk’s Novolog/Novorapid products respectively
  • If approved, Viatris’s insulin products would be the first biosimilars to receive the US FDA’s interchangeable designations

Click here to­ read full press release/ article | Ref: Viatris | Image: Viatris

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post